CDA | Evidence Driven
CDA | Evidence Driven

dimethyl fumarate

Details

Files
Generic Name:
dimethyl fumarate
Project Status:
Active
Therapeutic Area:
Multiple Sclerosis (MS)
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
SX0751-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
​Radiologically Isolated Syndrome (RIS).
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Submission receivedJuly 11, 2024
Review initiatedJuly 12, 2024
Expert committee meeting (initial)November 21, 2024
Draft recommendation posted for stakeholder feedbackDecember 12, 2024
End of feedback periodJanuary 03, 2025

Files

Draft Report View PDF
Draft Supplemental Materials View PDF
Draft Recommendation View PDF
Responses to the Questions From the Drug Programs View PDF
Proposed Scope View PDF
Last Updated : December 12, 2024